Clinical outcomes of

Female Humans Middle Aged Anaplastic Lymphoma Kinase / antagonists & inhibitors Carcinoma, Non-Small-Cell Lung / drug therapy Crizotinib / therapeutic use Denmark / epidemiology Lung Neoplasms / drug therapy Protein Kinase Inhibitors / therapeutic use Retrospective Studies
ALK+non-small cell lung cancer clinical outcome nationwide prevalence retrospective treatment use and duration

Journal

Acta oncologica (Stockholm, Sweden)
ISSN: 1651-226X
Titre abrégé: Acta Oncol
Pays: England
ID NLM: 8709065

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 27 11 2023
pubmed: 10 10 2023
entrez: 10 10 2023
Statut: ppublish

Résumé

Real-world clinical outcomes of anaplastic lymphoma kinase positive ( A national pathology database with complete coverage was used to identify A total of 209 This study gives insights into the treatment and outcome of

Sections du résumé

BACKGROUND UNASSIGNED
Real-world clinical outcomes of anaplastic lymphoma kinase positive (
MATERIALS AND METHODS UNASSIGNED
A national pathology database with complete coverage was used to identify
RESULTS UNASSIGNED
A total of 209
CONCLUSION UNASSIGNED
This study gives insights into the treatment and outcome of

Identifiants

DOI: 10.1080/0284186X.2023.2263153 PMID: 37815923
pubmed: 37815923
doi: 10.1080/0284186X.2023.2263153
doi:

Substances chimiques

Anaplastic Lymphoma Kinase EC 2.7.10.1
Crizotinib 53AH36668S
Protein Kinase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1775-1783

Auteurs

Karin Holmskov Hansen (KH)

Department of Oncology, Odense University Hospital, Odense, Denmark.

Jakob Sidenius Johansen (JS)

Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.

Edyta Maria Urbanska (EM)

Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Peter Meldgaard (P)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Peter Hjorth-Hansen (P)

Department of Oncology, Aalborg University Hospital, Aalborg, Denmark.

Charlotte Kristiansen (C)

Department of Oncology, Vejle Hospital, University Hospital of Southern Denmark, Vejle, Denmark.

Miroslaw Stelmach (M)

Department of Oncology, Næstved Hospital, Næstved, Denmark.

Eric Santoni-Rugiu (E)

Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Maiken Parm Ulhøi (MP)

Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.

Anders Bondo Dydensborg (AB)

Takeda Pharma A/S, Copenhagen, Denmark.

Christina Dünweber (C)

Takeda Pharma A/S, Copenhagen, Denmark.

Jon Lykkegaard Andersen (JL)

Department of Oncology, Herlev and Gentofte University Hospital, Copenhagen, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinical outcomes of
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Clinical outcomes of
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs à activité tyrosine kinase › Kinase du lymphome anaplasique › Clinical outcomes of
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Clinical outcomes of
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Aminopyridines › Crizotinib › Clinical outcomes of
questionsmedicales.fr › Régions géographiques › Europe › Pays nordiques et scandinaves › Danemark › Clinical outcomes of
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Clinical outcomes of
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Clinical outcomes of
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Clinical outcomes of